लोड हो रहा है...
Melanoma driver mutations and immune therapy
Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss...
में बचाया:
| में प्रकाशित: | Oncoimmunology |
|---|---|
| मुख्य लेखकों: | , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Taylor & Francis
2016
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4910708/ https://ncbi.nlm.nih.gov/pubmed/27467925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1051299 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|